A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
The company dribbles out more data on IMA203, and the numbers head in the right direction.